Report Date: Wednesday, July 29, 2026 (before market open) | Event: 2026Q2 Earnings Call
This is arguably the most important print of the year for HUM shareholders, if only because of how far and how fast the stock has moved. Shares bottomed near $175 in mid-February 2026 (after the 2025 Star Ratings litigation loss and a guidance reset) and have since rallied to roughly $389–400, an increase of well over 100% in five months, with the stock touching an all-time high above $409 in early July. The move accelerated through June and July on a combination of:
Why this matters for tomorrow: expectations have risen sharply alongside the stock. A "good enough" quarter that would have driven a big rally in February may now be viewed as merely in-line, raising the bar for what constitutes a genuine beat-and-raise.
Humana's Q1 was framed internally as "on track." Key figures:
On the Q1 call, CFO Celeste Mellet guided Q2 Insurance segment MLR to run "slightly above 91%," a smaller step-up than the prior year because 2025's Q1 benefited from heavier reserve releases. Management said early indicators through April — risk scores, admits-per-thousand, pharmacy claims — were running in line to better than guidance, even after adjusting for a milder flu season. Investors will want an update on whether that favorable trend held through Q2, historically viewed as the "real tell" quarter for full-year claims experience, as one analyst noted on the Q1 call.
IBNR grew ~35% sequentially in Q1, well ahead of membership growth, which management characterized as a prudent/conservative reserving posture given elevated new-member growth (individual MA membership guided to grow ~25% for FY2026). Watch for commentary on whether that cushion gets released as claims data matures, which could be an EPS tailwind, or whether it proves warranted.
Management said explicitly on the Q1 call that it would "share more about our progress in the Q2 earnings call once the hybrid season is complete," referring to the CMS call-center "secret shopper" testing that determines a key input into 2028 Star Ratings. This is likely the single most market-moving disclosure of the call, given the entire 2028 margin-recovery narrative depends on Humana returning to top-quartile Stars (4-star+) status. Humana is also awaiting a Fifth Circuit appellate ruling on its lawsuit challenging the 2025 (Bonus Year 2026) Star Ratings methodology, having lost twice in district court; any update here would also be notable, though litigation timing is outside management's control.
CEO Jim Rechtin has been explicit that the funding-vs.-medical-trend gap is larger heading into the 2027 bid cycle than it was a year ago, meaning Humana will need to trim benefits again for 2027 even with a friendlier CMS rate notice, prioritizing margin progress first, member retention second, and growth a "distant third." Listen for how much detail management is willing to give on the shape of 2027 guidance (typically previewed in more detail at Q3/Investor Day) and whether commentary reinforces confidence in the 2028 3%+ margin target first laid out at the June 2025 Investor Day.
Watch whether the one-time cost drags flagged in Q1 (ACO REACH/skin substitutes true-up, Villages Health integration, MaxHealth deal costs) reversed as promised, and for further detail on MaxHealth (Florida primary care) integration, which added ~59,000 patients and 54 centers. CenterWell primary care patient count grew 22.5% sequentially in Q1.
Humana said it needed to decide by mid-2026 whether to exercise call options on early primary-care clinic cohorts from its Welsh, Carson, Anderson & Stowe joint venture; a full Welsh Carson put exercise was estimated at $1.0–$1.5 billion of cash obligation in 2027. Also watch capital return commentary — Humana has kept buybacks limited to offsetting dilution and held the dividend flat, with management signaling both could increase as cash flow and funding capacity improve under the 2028 plan.
UnitedHealth's Q2 2026 results (reported ahead of Humana) showed sharply higher earnings and a raised full-year outlook, citing improved Medicare Advantage and Optum Health performance, though it flagged that commercial medical cost trends remain elevated — a broadly reassuring signal for the sector's MA cost trajectory heading into Humana's print. Other large payers reported a "mixed" quarter overall, with elevated MA and ACA exchange costs pressuring several peers even as UnitedHealth outperformed.
| Metric | FY2026 Guidance |
|---|---|
| Adjusted EPS | at least $9.00 |
| GAAP EPS | at least $8.36 |
| Total revenue | at least $160 billion |
| Insurance segment benefit ratio | 92.75% ± 25 bps |
| Consolidated operating cost ratio | 10.0% ± 25 bps |
| Individual MA membership growth | ~25% |
| Group MA membership growth | ~150,000 |
| Individual stand-alone PDP growth | ~1,000,000 |
| State-based (Medicaid) contracts growth | 25,000–100,000 |
| Insurance segment income from operations | ~breakeven (GAAP) |
| CenterWell segment income from operations | $1.3B–$1.8B (GAAP) / $1.5B–$2.0B (adjusted) |
| Operating cash flow | $2.5B–$2.9B |
Any change to these figures — up or down — will likely be the biggest swing factor for the stock reaction, given how much good news (rate notice, cost trend optimism, Stars hope) is already embedded in the current share price.
Humana goes into this print with unusually high expectations after one of the largest rallies in the healthcare sector this year, fueled by a favorable 2027 CMS rate notice, easing sector-wide medical cost trend fears, and hope for a Star Ratings recovery. The Q1 setup (in-line-to-better claims trends, affirmed guidance, membership growth on track) was reassuring, but the Q2 print is the quarter management itself has flagged as the real test of underlying MA cost trends, and the call is expected to bring the first substantive update on Bonus Year 2028 Star Ratings progress — the single biggest lever behind the multi-year margin-recovery thesis that underpins the stock's re-rating.